2 terminated. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
| Phase 3 | 1 | Terminated 1 |
Follow Severe Preeclampsia: new trials by email Literature Review of Severe Preeclampsia trials Research Report on Severe Preeclampsia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Complement Regulation to Undo Systemic Harm in Preeclampsia Eculizumab - Preeclampsia, Severe Preeclampsia | Phase 2 | Terminated | Cedars-Sinai Medical Center | 2 | 2021-09-13 | 2023-11-29 |
| Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclampsia AMAG-423 (digoxin immune fab), Placebo - Severe Preeclampsia | Phase 2 / Phase 3 | Terminated | AMAG Pharmaceuticals, Inc. | 58 | 2017-04-12 | 2026-05-22 |
Pre-Eclampsia (2) · HELLP Syndrome (1)
Female Urogenital Diseases and Pregnancy Complications (2) · Hypertension, Pregnancy-Induced (2) · Pregnancy Complications (2) · Urogenital Diseases (2)
digoxin antibodies Fab fragments (1) · eculizumab (1)
AMAG Pharmaceuticals, Inc. (1) · Cedars-Sinai Medical Center (1)
United States (2) · Poland (1) · South Africa (1)